Skip to main content
Premium Trial:

Request an Annual Quote

Arc Bio Galileo Pathogen Solution, GPS-Transplant

Arc Bio has launched the Galileo Pathogen Solution product line and first product, GPS-Transplant, a research-use-only next-generation sequencing test to aid in monitoring post-transplant patients for viral infections. GPS-Transplant detects the most common viral infections among transplant patients, including cytomegalovirus, Epstein–Barr virus, BK virus, and human adenovirus. The test also detects different variances and genotypes of the viruses, as well as more rare infections. GPS-Transplant also offers the ability to detect antiviral resistance mutations, and performs simultaneous quantitative detection of more than 350 viral strains. It is a sample-to-report solution built around the Illumina NGS platform that consists of reagents, built-in assay controls, and Galileo Analytics, a cloud-based proprietary software that provides quick and reliable results, an intuitive user interface, and detailed, actionable reports. The analytics software leverages Arc Bio's curated pathogen database called ArcIve, and also incorporates AMR resistance prediction technology which Arc Bio launched last year.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.